Baxter drug joins group of high-profile Alzheimer's failures
This article was originally published in Scrip
Executive Summary
Baxter International said a therapy being tested for Alzheimer’s disease failed to meet its targets in a late-stage study, marking the latest high-profile clinical setback for treating the debilitating condition.